Spero Therapeutics Inc (SPRO) — Cash Flow Quality Index
Spero Therapeutics Inc (SPRO) has a Cash Flow Quality Index of -0.26x as of December 2025. Operating cash flow of $-8.35 Million is below net income of $31.52 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore how large is Spero Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Spero Therapeutics Inc Cash Flow Quality Index (2023–2025)
Historical Cash Flow Quality Index for Spero Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible equity quality of Spero Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Spero Therapeutics Inc (2023–2025)
Year-by-year earnings quality comparison for Spero Therapeutics Inc. For live market cap and the full company financial profile, see SPRO market cap overview.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -1.47x | $-12.62 Million | $8.57 Million | ▼ -1.8% |
| 2023 | -1.45x | $-32.99 Million | $22.81 Million | — |